These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. He P; Smith A; Gelissen IC; Ammit AJ Pharmacol Rep; 2019 Dec; 71(6):1219-1226. PubMed ID: 31669886 [TBL] [Abstract][Full Text] [Related]
3. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381 [TBL] [Abstract][Full Text] [Related]
4. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis. El Roz A; Bard JM; Huvelin JM; Nazih H Anticancer Res; 2012 Jul; 32(7):3007-13. PubMed ID: 22753765 [TBL] [Abstract][Full Text] [Related]
5. Impairment of trophoblast survival and differentiation by LXR ligands is prevented by cholesterol but not ABCA1 silencing. Harmon CM; McGonigal S; Larkin JC Placenta; 2018 Sep; 69():50-56. PubMed ID: 30213484 [TBL] [Abstract][Full Text] [Related]
6. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998 [TBL] [Abstract][Full Text] [Related]
7. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice. Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice. Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299 [TBL] [Abstract][Full Text] [Related]
9. Ozone-derived Oxysterols Affect Liver X Receptor (LXR) Signaling: A POTENTIAL ROLE FOR LIPID-PROTEIN ADDUCTS. Speen AM; Kim HH; Bauer RN; Meyer M; Gowdy KM; Fessler MB; Duncan KE; Liu W; Porter NA; Jaspers I J Biol Chem; 2016 Nov; 291(48):25192-25206. PubMed ID: 27703007 [TBL] [Abstract][Full Text] [Related]
10. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. Murthy S; Born E; Mathur SN; Field FJ J Lipid Res; 2002 Jul; 43(7):1054-64. PubMed ID: 12091489 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor-driven transcription of hepatic lipogenic genes in vivo. Nahon JE; Groeneveldt C; Geerling JJ; van Eck M; Hoekstra M Br J Pharmacol; 2018 Aug; 175(15):3175-3183. PubMed ID: 29774529 [TBL] [Abstract][Full Text] [Related]
12. Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels. Cui W; Sun Y; Wang Z; Xu C; Xu L; Wang F; Chen Z; Peng Y; Li R Neurochem Res; 2011 Oct; 36(10):1910-21. PubMed ID: 21630010 [TBL] [Abstract][Full Text] [Related]
13. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914 [TBL] [Abstract][Full Text] [Related]
14. Homocysteine accelerates atherosclerosis via inhibiting LXRα-mediated ABCA1/ABCG1-dependent cholesterol efflux from macrophages. Jin P; Bian Y; Wang K; Cong G; Yan R; Sha Y; Ma X; Zhou J; Yuan Z; Jia S Life Sci; 2018 Dec; 214():41-50. PubMed ID: 30393020 [TBL] [Abstract][Full Text] [Related]
15. Reduced silent information regulator 1 signaling exacerbates sepsis-induced myocardial injury and mitigates the protective effect of a liver X receptor agonist. Han D; Li X; Li S; Su T; Fan L; Fan WS; Qiao HY; Chen JW; Fan MM; Li XJ; Wang YB; Ma S; Qiu Y; Tian ZH; Cao F Free Radic Biol Med; 2017 Dec; 113():291-303. PubMed ID: 28993270 [TBL] [Abstract][Full Text] [Related]
16. NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists. Srivastava RAK; Cefalu AB; Srivastava NS; Averna M Mol Cell Biochem; 2020 Oct; 473(1-2):247-262. PubMed ID: 32661772 [TBL] [Abstract][Full Text] [Related]
17. LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects. Spillmann F; Van Linthout S; Miteva K; Lorenz M; Stangl V; Schultheiss HP; Tschöpe C Atherosclerosis; 2014 Jan; 232(1):1-9. PubMed ID: 24401210 [TBL] [Abstract][Full Text] [Related]
18. Retinoic acid and liver X receptor agonist synergistically inhibit HIV infection in CD4+ T cells by up-regulating ABCA1-mediated cholesterol efflux. Jiang H; Badralmaa Y; Yang J; Lempicki R; Hazen A; Natarajan V Lipids Health Dis; 2012 Jul; 11():69. PubMed ID: 22676378 [TBL] [Abstract][Full Text] [Related]
19. Setosphapyrone C and D accelerate macrophages cholesterol efflux by promoting LXRα/ABCA1 pathway. Li T; Yin J; Ji Y; Lin P; Li Y; Yang Z; Hu S; Wang J; Zhang B; Koshti S; Wang J; Ji C; Guo S Arch Pharm Res; 2020 Aug; 43(8):788-797. PubMed ID: 32779151 [TBL] [Abstract][Full Text] [Related]
20. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits. Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]